Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 11 Jul 2016 Status changed from recruiting to discontinued because no participant enrolled for three years and no plan to continue study.
- 21 Mar 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
- 21 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.